Related Experiment Video
Updated: Jun 12, 2026
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Improving stroke risk stratification in atrial fibrillation
Gregory Y H Lip1, Jonathan L Halperin
1University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, England. g.y.h.lip@bham.ac.uk
Insights
The CHA2DS2-VASc score improves stroke risk assessment in atrial fibrillation patients. This validated tool helps determine appropriate antithrombotic therapy, simplifying treatment decisions for better patient outcomes.
Area of Science:
- Cardiology
- Thrombosis Research
Background:
- Current stroke risk stratification in atrial fibrillation (AF) relies on clinical trial data, with limitations in comprehensiveness.
- The CHADS(2) score is widely used but has recognized limitations in accurately assessing risk.
- A refined risk stratification approach is needed for nonvalvular AF patients.
Purpose of the Study:
- To introduce and validate the CHA2DS2-VASc score for improved stroke and thromboembolism risk stratification in atrial fibrillation patients.
- To compare the efficacy of CHA2DS2-VASc with the existing CHADS(2) score.
- To provide a simplified guideline for antithrombotic therapy decisions in AF.
Main Methods:
- Analysis of clinical trial cohorts to identify and weigh risk factors.
- Development of the CHA2DS2-VASc scoring system, assigning points to specific risk factors (Cardiac failure, Hypertension, Age, Diabetes, Stroke, Vascular disease, Sex category).
- Evaluation of the CHA2DS2-VASc score's performance in risk stratification and treatment guidance.
Main Results:
- The CHA2DS2-VASc score incorporates additional relevant risk factors (vascular disease, age 65-74, female sex) beyond CHADS(2).
- Assigns 2 points for stroke history or age ≥75, and 1 point for other factors.
- A CHA2DS2-VASc score of 0 indicates a truly low-risk patient, potentially managed without antithrombotic therapy, simplifying management.
Conclusions:
- The CHA2DS2-VASc score offers a more comprehensive and accurate risk stratification for stroke and thromboembolism in AF patients.
- This scoring system can guide decisions on oral anticoagulation, potentially reducing overtreatment and undertreatment.
- Implementation of CHA2DS2-VASc can streamline thromboprophylaxis strategies in atrial fibrillation management.
Abstract:
Risk factors for stroke and thromboembolism in patients with atrial fibrillation used in current risk stratification schema are derived largely from analyses of clinical trial cohorts, and the available data depend on the comprehensiveness of trial reports and whether specific risk factors were sought. The most commonly used schema is the Cardiac failure, Hypertension, Age, Diabetes, Stroke [Doubled] (CHADS(2)) score. Although simple and well validated, some limitations of CHADS(2) this schema are apparent. A more recent approach to risk stratification of patients with nonvalvular atrial fibrillation defines "major (definitive)" risk factors (eg, previous stroke/transient ischemic attack and age> or =75 years) and "clinically relevant non-major" risk factors (eg, heart failure, hypertension, diabetes, female gender, age 65-75 years, and atherosclerotic vascular disease). This scheme can be expressed as an acronym, CHA(2)DS(2)-VASc, denoting Cardiac failure or dysfunction, Hypertension, Age> or =75 [Doubled], Diabetes, Stroke [Doubled]-Vascular disease, Age 65-74, and Sex category [Female]), whereby 2 points are assigned for a history of stroke or age 75 years or more and 1 point each is assigned for age 65 to 74 years, a history of hypertension, diabetes, cardiac failure, and vascular disease. Patients with 1 definitive risk factor or a patient with a CHA(2)DS(2)-VASc score of 1 or more could be considered for oral anticoagulation, but a patient with a CHA(2)DS(2)-VASc score of 0 is truly low risk and could be managed with no antithrombotic therapy. This would simplify our approach to thromboprophylaxis in patients with atrial fibrillation.
More Related Videos
Related Concept Videos
01:26Atherosclerosis III: Management
01:23Atherosclerosis IV: Nursing Management
01:30Dysrhythmias V: Evaluating Dysrhythmias
01:29Venous Thrombosis III: Interprofessional Care